CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2008; 29(04): 12-18
DOI: 10.4103/0971-5851.51399
Original Article

Chemoradiation in locally advanced cervical cancer : A randomized trial

Sayan Kundu
Department of Radiotherapy, Medical College Hospital, Kolkata-700073, India
S Basu
Department of Radiotherapy, Medical College Hospital, Kolkata-700073, India
S Acharya
Department of Radiotherapy, Medical College Hospital, Kolkata-700073, India
A Dastidar
Department of Radiotherapy, Medical College Hospital, Kolkata-700073, India
A G Roy
Department of Radiotherapy, Medical College Hospital, Kolkata-700073, India
› Author Affiliations


Background: Radiation with concurrent chemotherapy (weekly cisplatin) is currently standard of care for locally advanced cervical cancer. Gemcitabine, a pyrimidine analogue is a potentially radio-sensitizing drug. We compared cisplatin and gemcitabine in the treatment of locally advanced cervical cancer. Methods: 90 patients with locally advanced squamous cell cancer of the cervix (stage IIB-IVA) were randomized to receive either cisplatin 40mg/m2 weekly or gemcitabine 150 mg/m2 weekly (45 patients in each arm) along with external beam radiation (50Gy in 25# over 5 weeks). This was followed by three insertions of high dose radiation (HDR) intracavitary brachytherapy one week apart. Results: At a median follow up of 13months, 25 (55.56%) patients were in complete response (CR) in the cisplatin arm compared to 22 patients (48.89%) [p=0.67] in gemcitabine arm. 10 patients (22.22%) in cisplatin arm had either died or lost to follow up compared to 11 patients in gemcitabine (24.44%) arm. Nausea/vomiting was higher in cisplatin arm. Diarrhea, skin reaction and hematological toxicity were more in gemcitabine arm. Conclusion: Cisplatin seems to be a better option than gemcitabine when used concurrently with radiation for locally advanced cervical cancer both in terms of response and toxicity.

Publication History

Article published online:
19 November 2021

© 2008. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153.
  • 2 Vreololjak E, Hamm W. Current state-of-the-art of concomitant chemoradiation in carcinoma cervix. Eur J Gynaecol Oncol 2003;24(6):475-479.
  • 3 Mc Cormack M, Thomas H. A phase IB study of gemcitabine and concurrent radiotherapy I carcinoma of the cervix. Ann Oncol 2000;11:88
  • 4 Christie DRH, Bull CA, Gebski V, et al. Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer. Radiother Oncol 1995;37:181- 189.
  • 5 Piver MS, Barlow JJ, Vongtama V, et al. Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. Am J Obstet Gynecol 1977;129:379-383.
  • 6 Perez CA, Grigsby PW. Adjuvant chemotherapy and irradiation in locally advanced squamous cell carcinoma of the uterine cervix. PPGO Updates 1993;1(4):1-20.
  • 7 Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-1161
  • 8 Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143.
  • 9 National Cancer Institute. Concurrent chemoradiation for cervical cancer. Clinical announcement, Washington DC; February 22, 1999.
  • 10 Hernandez P, Olivierra P, Ducnas-Gonzalez A, et al. Gemcitabine activity in cervical cancer cell line. Cancer Chemotherapy Pharmacol. 2001;48:488-492.
  • 11 Pattaranutapern P, Thirapakawong C, Chanshlka Y, et al. Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol Oncology. 2001;81:404-407.
  • 12 Alvarez AM, Mickiewicz E, Rodger J, et al. Radiotherapy with low-dose biweekly gemcitabine and cisplatin in locally advanced cervical carcinoma: stages IIA-IVA. Procc ASCO 2002;21:224a.
  • 13 Zarba JJ, Jaremtchuk AV, Gonzalez Jazey P, et al. A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma. Ann Oncol 2003;14:1285-1290.
  • 14 Duenas-Gonzalez A, Cetina-Perez L, Lopez-Graniel C, et al. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study. Int J Radiat Oncol Biol Phys 2005;61(3):817-823.
  • 15 Umanzor J, Aguiluz M, Pineda C, et al. Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial. Gynecol Oncol 2006;100(1):70-75. Epub 2005 Nov 8.
  • 16 Higgins R, Bussey M, Naumann W, et al. Concurrent carboplatin and paclitaxel with pelvic radiation therapy in the primary treatment of cervical cancer. Am J Obstet Gynecol 2007;197:205.e1-205.e7.